Clinical trials: Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

• Active, not recruiting
• Age: 12 years and older
• Phase 3
• Surgery or procedure
• Results posted

This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.

Conditions

Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma

Trial name

NCT03907488

Testing

Biospecimen Collection, Brentuximab Vedotin, Computed Tomography

Where

728 sites in United States, Canada and 1 more

Volunteers

994 people

Sponsor

National Cancer Institute (NCI)